Literature DB >> 18823825

Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

Patton Minkin1, Ming Zhao, Zhaoyuan Chen, Jan Ouwerkerk, Hans Gelderblom, Sharyn D Baker.   

Abstract

A rapid, sensitive and specific method was developed and validated using LC/MS/MS for determination of sunitinib in human plasma. Sample preparation involved a liquid-liquid extraction by the addition of 0.2mL of plasma with 4.0mL tert-butyl-methyl-ether extraction solution containing 25ng/mL of the internal standard clozapine. Separation of compounds was achieved on a C18 (50mmx2.1mm i.d., 3.5microm) analytical column using a mobile phase consisting of acetonitrile/H20 (65:35, v/v) containing 0.1% formic acid and isocratic flow at 0.150mL/min for 3min. The analytes were monitored by tandem-mass spectrometry with electrospray positive ionization. Linear calibration curves in human plasma were generated over the range of 0.2-500ng/mL with values for the coefficient of determination of >0.9950. Within- and between day precision and accuracy were < or =10%. The method was applied to the quantitation of sunitinib in plasma samples from a patient receiving daily oral therapy with sunitinib.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18823825      PMCID: PMC2612784          DOI: 10.1016/j.jchromb.2008.09.007

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  11 in total

Review 1.  PDGF receptors as cancer drug targets.

Authors:  Kristian Pietras; Tobias Sjöblom; Kristofer Rubin; Carl-Henrik Heldin; Arne Ostman
Journal:  Cancer Cell       Date:  2003-05       Impact factor: 31.743

2.  A small molecule-kinase interaction map for clinical kinase inhibitors.

Authors:  Miles A Fabian; William H Biggs; Daniel K Treiber; Corey E Atteridge; Mihai D Azimioara; Michael G Benedetti; Todd A Carter; Pietro Ciceri; Philip T Edeen; Mark Floyd; Julia M Ford; Margaret Galvin; Jay L Gerlach; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Michael A Insko; Andiliy G Lai; Jean-Michel Lélias; Shamal A Mehta; Zdravko V Milanov; Anne Marie Velasco; Lisa M Wodicka; Hitesh K Patel; Patrick P Zarrinkar; David J Lockhart
Journal:  Nat Biotechnol       Date:  2005-02-13       Impact factor: 54.908

Review 3.  FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.

Authors:  Bertrand W Parcells; Alan K Ikeda; Tiffany Simms-Waldrip; Theodore B Moore; Kathleen M Sakamoto
Journal:  Stem Cells       Date:  2006-01-12       Impact factor: 6.277

Review 4.  Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies.

Authors:  Torsten Kessler; Frauke Fehrmann; Ralf Bieker; Wolfgang E Berdel; Rolf M Mesters
Journal:  Curr Drug Targets       Date:  2007-02       Impact factor: 3.465

Review 5.  Sunitinib: from rational design to clinical efficacy.

Authors:  Laura Q M Chow; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

Review 6.  Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.

Authors:  Vicki L Goodman; Edwin P Rock; Ramzi Dagher; Roshni P Ramchandani; Sophia Abraham; Jogarao V S Gobburu; Brian P Booth; S Leigh Verbois; David E Morse; Cheng Yi Liang; Nallaperumal Chidambaram; Janet X Jiang; Shenghui Tang; Kooros Mahjoob; Robert Justice; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531

7.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors:  Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

Review 8.  Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.

Authors:  Robert Roskoski
Journal:  Biochem Biophys Res Commun       Date:  2005-10-04       Impact factor: 3.575

9.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

Authors:  Walter Fiedler; Hubert Serve; Hartmut Döhner; Michael Schwittay; Oliver G Ottmann; Anne-Marie O'Farrell; Carlo L Bello; Randy Allred; William C Manning; Julie M Cherrington; Sharianne G Louie; Weiru Hong; Nicoletta M Brega; Giorgio Massimini; Paul Scigalla; Wolfgang E Berdel; Dieter K Hossfeld
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

10.  A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.

Authors:  Carolyn D Britten; Fairooz Kabbinavar; J Randolph Hecht; Carlo L Bello; Jim Li; Charles Baum; Dennis Slamon
Journal:  Cancer Chemother Pharmacol       Date:  2007-05-16       Impact factor: 3.333

View more
  11 in total

1.  Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies.

Authors:  Rajneet K Oberoi; Rajendar K Mittapalli; James Fisher; William F Elmquist
Journal:  Chromatographia       Date:  2013-12-01       Impact factor: 2.044

Review 2.  Optimal use of targeted agents for advanced gastrointestinal stromal tumours.

Authors:  Peter Reichardt
Journal:  Oncology       Date:  2010-04-13       Impact factor: 2.935

3.  Therapeutic drug monitoring and tyrosine kinase inhibitors.

Authors:  Pauline Herviou; Emilie Thivat; Damien Richard; Lucie Roche; Joyce Dohou; Mélanie Pouget; Alain Eschalier; Xavier Durando; Nicolas Authier
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

4.  Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.

Authors:  Franziska Stehle; Kristin Schulz; Corinna Fahldieck; Jana Kalich; Rudolf Lichtenfels; Dagmar Riemann; Barbara Seliger
Journal:  J Biol Chem       Date:  2013-04-26       Impact factor: 5.157

5.  Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Authors:  Paola Di Gion; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Oxana Doroshyenko; Uwe Fuhr; Jürgen Wolf; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

6.  Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.

Authors:  Rana Rais; Ming Zhao; Ping He; Linping Xu; John F Deeken; Michelle A Rudek
Journal:  Biomed Chromatogr       Date:  2012-01-18       Impact factor: 1.902

7.  Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.

Authors:  Shuiying Hu; Zhaoyuan Chen; Ryan Franke; Shelley Orwick; Ming Zhao; Michelle A Rudek; Alex Sparreboom; Sharyn D Baker
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

8.  Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application.

Authors:  Qingyu Zhou; James M Gallo
Journal:  J Pharm Biomed Anal       Date:  2009-10-12       Impact factor: 3.935

9.  A biodegradable perivascular wrap for controlled, local and directed drug delivery.

Authors:  William G Sanders; Paul C Hogrebe; David W Grainger; Alfred K Cheung; Christi M Terry
Journal:  J Control Release       Date:  2012-04-27       Impact factor: 9.776

10.  Marginal increase of sunitinib exposure by grapefruit juice.

Authors:  Nielka P van Erp; Sharyn D Baker; Anthe S Zandvliet; Bart A Ploeger; Margaret den Hollander; Zhaoyuan Chen; Jan den Hartigh; Jacqueline M C König-Quartel; Henk-Jan Guchelaar; Hans Gelderblom
Journal:  Cancer Chemother Pharmacol       Date:  2010-05-29       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.